Form 4 for MRNA Moderna
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-03 · accession 0001127602-25-007904 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-04 | 2025-03-03 | MRNA | SAGAN PAUL | Dir | P - Purchase | $31.76 | +31.6K | 312.0K | +11% | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | P | A | 31,620 | $31.76 | 312,027 | I By: The Paul Sagan Revocable Trust | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.46 to $31.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F2) This balance reflects the transfer of 90,000 shares of the Issuer's common stock from The Paul Sagan Revocable Trust to The Chatham Trust on November 21, 2024. |